Your browser doesn't support javascript.
loading
Cost analysis for the implementation of a medication review with follow-up service in Spain.
Noain, Aranzazu; Garcia-Cardenas, Victoria; Gastelurrutia, Miguel Angel; Malet-Larrea, Amaia; Martinez-Martinez, Fernando; Sabater-Hernandez, Daniel; Benrimoj, Shalom I.
Afiliación
  • Noain A; Pharmaceutical Care Research Group, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n., 18071, Granada, Spain.
  • Garcia-Cardenas V; Graduate School of Health, University of Technology Sydney, Broadway New South Wales 2007, P.O. Box 123, Sydney, Australia. victoria.garciacardenas@uts.edu.au.
  • Gastelurrutia MA; Pharmaceutical Care Research Group, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n., 18071, Granada, Spain.
  • Malet-Larrea A; Pharmaceutical Technology Department, Faculty of Pharmacy, University of the Basque Country, 01006, Vitoria, Spain.
  • Martinez-Martinez F; Pharmaceutical Care Research Group, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n., 18071, Granada, Spain.
  • Sabater-Hernandez D; Graduate School of Health, University of Technology Sydney, Broadway New South Wales 2007, P.O. Box 123, Sydney, Australia.
  • Benrimoj SI; Graduate School of Health, University of Technology Sydney, Broadway New South Wales 2007, P.O. Box 123, Sydney, Australia.
Int J Clin Pharm ; 39(4): 750-758, 2017 Aug.
Article en En | MEDLINE | ID: mdl-28434119
Background Medication review with follow-up (MRF) is a professional pharmacy service proven to be cost-effective. Its broader implementation is limited, mainly due to the lack of evidence-based implementation programs that include economic and financial analysis. Objective To analyse the costs and estimate the price of providing and implementing MRF. Setting Community pharmacy in Spain. Method Elderly patients using poly-pharmacy received a community pharmacist-led MRF for 6 months. The cost analysis was based on the time-driven activity based costing model and included the provider costs, initial investment costs and maintenance expenses. The service price was estimated using the labour costs, costs associated with service provision, potential number of patients receiving the service and mark-up. Main outcome measures Costs and potential price of MRF. Results A mean time of 404.4 (SD 232.2) was spent on service provision and was extrapolated to annual costs. Service provider cost per patient ranged from €196 (SD 90.5) to €310 (SD 164.4). The mean initial investment per pharmacy was €4594 and the mean annual maintenance costs €3,068. Largest items contributing to cost were initial staff training, continuing education and renting of the patient counselling area. The potential service price ranged from €237 to €628 per patient a year. Conclusion Time spent by the service provider accounted for 75-95% of the final cost, followed by initial investment costs and maintenance costs. Remuneration for professional pharmacy services provision must cover service costs and appropriate profit, allowing for their long-term sustainability.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacéuticos / Análisis Costo-Beneficio / Revisión de la Utilización de Medicamentos / Servicios Comunitarios de Farmacia / Rol Profesional Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Int J Clin Pharm Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacéuticos / Análisis Costo-Beneficio / Revisión de la Utilización de Medicamentos / Servicios Comunitarios de Farmacia / Rol Profesional Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Int J Clin Pharm Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos